Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study to Compare Oral Masitinib to Placebo in Treatment of Patients With Smouldering or Indolent Severe Systemic Mastocytosis, Unresponsive to Optimal Symptomatic Treatment

NCT04333108 is registered in ClinicalTrials.gov with AB Science as lead sponsor.

NCT NCT04333108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04333108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study to Compare Oral Masitinib to Placebo in Treatment of Patients With Smouldering or Indolent Severe Systemic Mastocytosis, Unresponsive to Optimal Symptomatic Treatment
Lead sponsor
AB Science
Phase
Phase 3
Overall status
Unknown status
Start date
July 1, 2020
Completion date
June 30, 2025
Enrollment
140 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

indolent systemic mastocytosis